Clinical benefit of treatment with eribulin mesylate for metastatic triple‐negative breast cancer: Long‐term outcomes of patients treated in the US community oncology setting

INTRODUCTION: Real‐world data are critical to demonstrate the consistency of evidence and external generalizability of randomized controlled trials (RCTs). This study examined characteristics and outcomes of metastatic triple‐negative breast cancer (mTNBC) patients treated with eribulin mesylate at...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer Med
Glavni autori: Mougalian, Sarah S., Copher, Ronda, Kish, Jonathan K., McAllister, Lindsay, Wang, Zhixiao, Broscious, Mary, Garofalo, David, Radtchenko, Janna, Feinberg, Bruce A.
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2018
Teme:
Clinical Cancer Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6144147/
https://ncbi.nlm.nih.gov/pubmed/30066497
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1705
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items